Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com Development of customized treatments for neurodegenerative disease focused on immune-inflammatory modulation through novel use of NCKAP1 in the regulation of microglial cell
Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com We identify a cell-permeable peptide, dNP2, which efficiently delivers proteins into mouse and human T cells, as well as various tissues. Introduction/BackgroundWe
Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com The present invention relates to a medical aspirator, and more particularly, to a device for draining blood or exudate generated in a
Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com Provide a hydrocolloid-form bio-patch which has warmth keeping ability, air permeability, is waterproof, and improved exudation absorption ability. Description of Technology Technology Green
Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com A research team from Hanyang University in South Korea has developed a new technology for discovering therapeutic target genes for individual cancer patients with
Opportunity ContactJames Noh, CEOSeoul, South Korea Oncobix Oncology Biosciences Website Pharmalicensing.com Mutation in the kinase region of the epidermal growth factor receptor (EGFR) is found in some non-small cell lung cancer patients
Opportunity ContactEnikő Koppány, Business Development ManagerSzeged, Hungary University of Szeged Website Pharmalicensing.com The recognition of Mild Cognitive Impairment (MCI) is one of the most difficult tasks of clinical psychiatry. Current tests are
Opportunity ContactEnikő Koppány, Business Development ManagerSzeged, Hungary University of Szeged Website Pharmalicensing.com The WYKYW pentapeptide is an endocytosis routing sequence for cell delivery of therapeutic macromolecules at therapeutically relevant nanomolar concentrations and
Opportunity ContactEnikő Koppány, Business Development ManagerSzeged, Hungary University of Szeged Website Pharmalicensing.com The application of desethamiodarone (DEA) in the treatment of arrhythmias would be more effective than chronic amiodarone (AMIO) treatment with
Opportunity ContactChristoph Schäfer, CEOBubendorf, Switzerland CIS Pharma Website Pharmalicensing.com The Cefuroxime Application System is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis. Introduction/BackgroundEvery year, 20